OTCMKTS:ALPMY - ASTELLAS PHARMA/ADR Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $14.53 -0.28 (-1.89 %) (As of 12/16/2018 04:00 PM ET)Previous Close$14.53Today's Range$14.51 - $14.6252-Week Range$12.35 - $17.99Volume87,824 shsAverage Volume79,840 shsMarket Capitalization$28.77 billionP/E Ratio18.39Dividend Yield1.96%Beta0.45 ProfileDiscussionAnalyst RatingsChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. It also provides Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. In addition, it offers Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, enfortumab vedotin, zolbetuximab, roxadustat, and fezolinetant for oncology indications. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. Receive ALPMY News and Ratings via Email Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ALPMY Previous Symbol CUSIPN/A Webwww.astellas.com Phone813-3244-3000 Debt Debt-to-Equity Ratio0.04 Current Ratio1.93 Quick Ratio1.59 Price-To-Earnings Trailing P/E Ratio18.39 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$12.00 billion Price / Sales2.40 Cash Flow$1.0168 per share Price / Cash Flow14.29 Book Value$5.52 per share Price / Book2.63 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$1.48 billion Net Margins13.49% Return on Equity13.46% Return on Assets9.37% Miscellaneous Employees16,617 Outstanding Shares1,980,000,000Market Cap$28.77 billion OptionableNot Optionable ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Frequently Asked Questions What is ASTELLAS PHARMA/ADR's stock symbol? ASTELLAS PHARMA/ADR trades on the OTCMKTS under the ticker symbol "ALPMY." When did ASTELLAS PHARMA/ADR's stock split? How did ASTELLAS PHARMA/ADR's stock split work? ASTELLAS PHARMA/ADR's stock split on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were distributed to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of ASTELLAS PHARMA/ADR stock prior to the split would have 125 shares after the split. How were ASTELLAS PHARMA/ADR's earnings last quarter? ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) released its quarterly earnings data on Wednesday, April, 25th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.15 by $0.05. The business had revenue of $2.78 billion for the quarter. ASTELLAS PHARMA/ADR had a net margin of 13.49% and a return on equity of 13.46%. View ASTELLAS PHARMA/ADR's Earnings History. When is ASTELLAS PHARMA/ADR's next earnings date? ASTELLAS PHARMA/ADR is scheduled to release their next quarterly earnings announcement on Tuesday, December 18th 2018. View Earnings Estimates for ASTELLAS PHARMA/ADR. What is the consensus analysts' recommendation for ASTELLAS PHARMA/ADR? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASTELLAS PHARMA/ADR in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ASTELLAS PHARMA/ADR. Has ASTELLAS PHARMA/ADR been receiving favorable news coverage? Press coverage about ALPMY stock has trended somewhat positive on Sunday, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ASTELLAS PHARMA/ADR earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. Who are some of ASTELLAS PHARMA/ADR's key competitors? Some companies that are related to ASTELLAS PHARMA/ADR include Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG), Allergan (AGN), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY) and Alexion Pharmaceuticals (ALXN). Who are ASTELLAS PHARMA/ADR's key executives? ASTELLAS PHARMA/ADR's management team includes the folowing people: Mr. Kenji Yasukawa Ph.D., Pres, CEO & Director (Age 58)Mr. Chikashi Takeda, CFO & Sr. Corp. Exec.Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Corp. Exec.Ms. Linda Friedman, Gen. Counsel & VPMr. Jeffrey A. Winton, Chief Communications Officer and Sr. VP of Corp. Affairs (Age 60) How do I buy shares of ASTELLAS PHARMA/ADR? Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ASTELLAS PHARMA/ADR's stock price today? One share of ALPMY stock can currently be purchased for approximately $14.53. How big of a company is ASTELLAS PHARMA/ADR? ASTELLAS PHARMA/ADR has a market capitalization of $28.77 billion and generates $12.00 billion in revenue each year. ASTELLAS PHARMA/ADR employs 16,617 workers across the globe. What is ASTELLAS PHARMA/ADR's official website? The official website for ASTELLAS PHARMA/ADR is http://www.astellas.com. How can I contact ASTELLAS PHARMA/ADR? ASTELLAS PHARMA/ADR's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000. MarketBeat Community Rating for ASTELLAS PHARMA/ADR (OTCMKTS ALPMY)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 152 (Vote Outperform)Underperform Votes: 108 (Vote Underperform)Total Votes: 260MarketBeat's community ratings are surveys of what our community members think about ASTELLAS PHARMA/ADR and other stocks. Vote "Outperform" if you believe ALPMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPMY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/16/2018 by MarketBeat.com StaffFeatured Article: What are the risks of holding treasury bonds?